Premium
Topiramate for smoking cessation
Author(s) -
KHAZAAL YASSER,
CORNUZ JACQUES,
BILANCIONI ROMAIN,
ZULLINO DANIELE FABIO
Publication year - 2006
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/j.1440-1819.2006.01518.x
Subject(s) - topiramate , smoking cessation , medicine , abstinence , addiction , anesthesia , psychiatry , epilepsy , pathology
Due to its AMPA (α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid)/kainate antagonism, topiramate would be particularly interesting in addiction treatment. Flexible‐dose topiramate was prescribed to 13 smokers (10 smokers who wanted to stop smoking, and three who received topiramate for other reasons). Six out of 13 smokers were abstinent at 2 months and two more subjects had reduced their cigarette consumption by >50%. With one exception, temporary reduction of the number of smoked cigarettes preceded definitive abstinence at month 2. Three more subjects who achieved a momentary reduction had, however, to interrupt the treatment due to intolerable side‐effects. Controlled trials are needed to confirm these preliminary observations.